Neuropathic pain represents a significant clinical challenge in older adults, requiring safe long-term management. Clinicians frequently prescribe gabapentinoids or serotonin-norepinephrine reuptake inhibitors for persistent symptoms. However, therapeutic selection in patients aged 65 and older demands careful consideration of adverse events, including gastrointestinal bleeding risk. While anti-inflammatory drugs cause known mucosal damage, the comparative gastrointestinal safety of neuropathic agents remains less clear. A 2026 target trial emulation study evaluated gastrointestinal bleeding risk between gabapentin and duloxetine initiators in senior patients.

Background and Clinical Rationale in Geriatric Care

Managing chronic neuropathic pain in older patients presents distinct clinical hurdles due to altered drug pharmacokinetics and frequent multimorbidity. Gabapentin, a calcium channel alpha-2-delta ligand, and duloxetine, a serotonin-norepinephrine reuptake inhibitor, are widely prescribed for neuropathic conditions like diabetic neuropathy and post-herpetic neuralgia. Despite widespread adoption, treatment decisions often focus on pain efficacy while underestimating organ-specific adverse effects. Older adults face elevated baseline risks for mucosal ulceration and gastrointestinal bleeding. Serotonergic agents like duloxetine inhibit platelet serotonin reuptake, potentially increasing upper and lower gastrointestinal bleeding risks. Conversely, gabapentin lacks direct antiplatelet activity, though comparative safety data in real-world geriatric populations remained limited. This knowledge gap creates clinical ambiguity for physicians balancing pain relief against serious drug-induced bleeding complications. Evaluating observational data through rigorous target trial emulation methodology provides essential clarity to guide evidence-based prescribing in aging populations.

Target Trial Emulation Study Methodology

To address this critical safety question, researchers conducted an active-comparator cohort study using the TriNetX US Collaborative Network database. The investigators utilized target trial emulation methodology to minimize selection bias, confounding by indication, and immortal time bias. The study included patients aged 65 years and older diagnosed with neuropathic pain between January 2020 and December 2024. Exclusions applied to individuals with prior gastrointestinal bleeding, major depressive disorder, or baseline thrombocytopenia. Patients were categorized into gabapentin or duloxetine initiation groups. Propensity score matching balanced demographics, baseline comorbidities, concomitant medications, and healthcare utilization. The primary outcome was 24-month gastrointestinal bleeding risk analyzed using Cox proportional hazards regression models. Secondary end points included upper and lower gastrointestinal bleeding sub-analyses, all-cause mortality, and emergency hospitalizations. Negative control outcomes were integrated to evaluate residual unmeasured confounding.

Key Study Findings on Gastrointestinal Bleeding Risk

The study evaluated 62,926 older patients with neuropathic pain, including 55,236 gabapentin initiators and 7,690 duloxetine initiators, yielding 7,599 propensity score-matched pairs. Over 24 months, patients initiating gabapentin demonstrated a significantly lower incidence of gastrointestinal bleeding compared to duloxetine initiators. Gastrointestinal bleeding occurred in 1.22% of gabapentin users versus 2.49% of duloxetine users, reflecting an absolute risk reduction of 1.27%. Cox regression analysis confirmed a reduced hazard for gabapentin (hazard ratio 0.86, 95% confidence interval 0.84 to 0.89, p < 0.001). Secondary analyses showed that gabapentin was associated with lower rates of both upper and lower gastrointestinal bleeding events. Furthermore, gabapentin initiation correlated with reduced secondary end points, including lower all-cause mortality and fewer emergency hospitalizations. Negative control analyses validated these findings, indicating that residual confounding did not explain the lower observed risk.

Mechanistic Insights and Pathophysiological Considerations

The observed difference in bleeding risk between gabapentin and duloxetine aligns with established pharmacological mechanisms. Duloxetine inhibits serotonin reuptake, increasing synaptic serotonin levels. However, blood platelets cannot synthesize serotonin and rely on membrane transporters to accumulate it. By blocking serotonin reuptake, duloxetine depletes platelet serotonin content, impairing platelet aggregation and blunting hemostatic responses during vascular mucosal injury. When combined with subclinical mucosal lesions, impaired aggregation heightens gastrointestinal bleeding vulnerability. In contrast, gabapentin selectively binds the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, modulating neurotransmitter release without affecting serotonin pathways or platelet function. Furthermore, older adults frequently use concurrent nonsteroidal anti-inflammatory drugs, antiplatelet therapies, or anticoagulants, which amplify the serotonergic bleeding risk associated with duloxetine. Understanding these mechanisms allows clinicians to select analgesics that align with individual gastrointestinal risk profiles.

Clinical Implications for Geriatric Neuropathic Pain Management

These real-world findings provide actionable guidance for clinical decision-making in geriatric pain management. While efficacy remains paramount, comparative safety profiles must inform drug selection in vulnerable older adults. For elderly patients presenting with elevated bleeding risk factors—such as advanced age, ulcer history, chronic kidney disease, or concomitant anticoagulant therapy—gabapentin represents a safer therapeutic choice regarding bleeding risk. Conversely, when duloxetine is preferred for specific indications like comorbid musculoskeletal pain, clinicians should exercise heightened monitoring. Implementing protective strategies, such as co-prescribing proton pump inhibitors or avoiding nonsteroidal anti-inflammatory drugs, helps mitigate gastrointestinal complications. Ultimately, personalized prescribing requires evaluating individual patient risk factors, drug interactions, renal function, and underlying organ vulnerabilities. Incorporating target trial emulation evidence into clinical workflows supports safer, individualized care for older adults with neuropathic pain.

Frequently Asked Questions

Why does duloxetine carry a higher gastrointestinal bleeding risk than gabapentin in older adults?

Duloxetine inhibits serotonin reuptake, which depletes serotonin inside blood platelets. Because platelets require serotonin for proper aggregation and clot formation, duloxetine impairs normal hemostasis, increasing the risk of mucosal bleeding throughout the gastrointestinal tract. In contrast, gabapentin acts on calcium channels without affecting serotonin transporters or platelet function, preserving normal coagulation mechanisms and resulting in lower overall bleeding rates.

Should older patients currently taking duloxetine for neuropathic pain be immediately switched to gabapentin?

Medication regimens should not be abruptly altered without comprehensive clinical evaluation. Clinicians must weigh individual pain control, psychiatric considerations, and overall bleeding risk before adjusting therapy. Patients who are achieving good pain relief on duloxetine without bleeding signs or high-risk factors may safely continue treatment, potentially alongside gastroprotective measures. Any therapeutic transition should involve gradual tapering to prevent withdrawal symptoms.

What clinical strategies can lower gastrointestinal bleeding risk when prescribing neuropathic pain medications?

To minimize gastrointestinal bleeding risk, clinicians should carefully screen patients for baseline risk factors, including ulcer history, advanced age, and concurrent use of nonsteroidal anti-inflammatory drugs or anticoagulants. When prescribing serotonergic agents like duloxetine, co-prescribing proton pump inhibitors can protect gastric mucosa. Additionally, choosing non-serotonergic alternatives like gabapentin for high-risk individuals offers an effective strategy to lower hemorrhage complications.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Agrawal N et al. Risk of gastrointestinal bleeding with gabapentin versus duloxetine in older adults with neuropathic pain: a target trial emulation cohort study. Naunyn Schmiedebergs Arch Pharmacol. 2026 Aug 09. doi: 10.1007/s00210-026-05807-7. PMID: 42571673.
2. Laporte JR, Ibañez L, Vidal X, Vendrell L, Leone R. Upper gastrointestinal bleeding associated with selective serotonin reuptake inhibitors, other antidepressants, and nonsteroidal anti-inflammatory drugs. Arch Intern Med. 2004;164(4):400-406.
3. Li H, Cheng Y, Ahl J, Skljarevski V. Observational study of upper gastrointestinal tract bleeding events in patients taking duloxetine and nonsteroidal anti-inflammatory drugs: a case-control analysis. Clin Ther. 2014;36(10):1417-1425.